Revenues Rise at Shire - Analyst Blog
May 02 2011 - 11:32AM
Zacks
Shire plc’s (SHPGY) first quarter 2011 earnings
(excluding special items) of $1.23 per ADS surpassed the year-ago
earnings by $0.22. Earnings were boosted by higher revenues. A
lower adjusted effective tax rate also impacted earnings positively
in the reported quarter. The Zacks Consensus Estimate was
$1.20.
Quarter in Detail
Quarterly revenues increased 19% to $972 million, well above the
Zacks Consensus Estimate of $945 million. Increased product sales
helped boost revenues. The rise in product sales more than offset
the decline in royalties during the first quarter of 2011.
Product sales went up 24% to $889 million. Product sales were
pushed up by strong performances of Vyvanse (up 31% to $202.3
million), Replagal (up 55% to $105.4 million), and Lialda (up 37%
to $87.1 million). Newly launched Intuniv and Vpriv also performed
well, registering sales of $59 million and $41.9 million,
respectively.
However, royalties declined 23% to $73.6 million. Royalty
revenue mainly comprises income earned on the sale of the
authorized generic version of Adderall XR, 3TC and Zeffix. During
the fourth quarter, Shire received royalties from Impax
Laboratories Inc. (IPXL) for Adderall XR (down 59%) and
GlaxoSmithKline (GSK) for 3TC and Zeffix (down
3%).
Adjusted research & development (R&D) costs climbed 36%
to $173.2 million in the reported quarter. Increased investments in
R&D programs contributed to the rise. Selling, general &
administrative (SG&A) expenses climbed 14% to $352.2
million.
Selling, general & administrative (SG&A) expenses
climbed 14% to $352.2 million. The inclusion of the operating
expenses of Movetis, acquired late last year, led to the rise in
SG&A expenses. Moreover, the costs incurred by Shire to
maintain the sales growth displayed by its products also led to the
rise.
Outlook
In addition to disclosing financial results, Shire also provided
an outlook for 2011. For 2011, Shire is anticipating impressive
revenue and earnings growth. Product sales are expected to register
growth in line with that witnessed in 2010. The company expects the
year-over-year increase in 2011 adjusted R&D and SG&A
expenses (combined) to be at the upper end of the 10%-13% range.
Adjusted effective tax-rate is forecasted in the range of 22%-24%
for 2011.
Our Recommendation
We currently have a Neutral recommendation on Shire, which is
supported by a Zacks #3 Rank (short-term Hold rating).
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
IMPAX LABORATRS (IPXL): Free Stock Analysis Report
SHIRE PLC-ADR (SHPGY): Free Stock Analysis Report
Zacks Investment Research
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From May 2024 to Jun 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jun 2023 to Jun 2024